

Overview

Keywords & Expertise

Objectives

Deliverables

**COST Policy Plans** 

Network of Proposers

**Action Parties** 

MC Observers

MC Participants

#### Leadership Positions

MC Decisions

**Networking Tools** 

« COST Actions



COST Action CA19114, Network for Optimized Astatine labeled Radiopharmaceuticals

Action Status: Running

#### **Action Chair and Vice Chair**

Dr Jean-François GESTIN **Action Chair** 

Dr Emma Aneheim

# **Working Groups**

Action Vice Chair

Please verify/update the approximate number of participants per Working Group and the Working Group Leader name (by linking this role to the eCOST profile of the MC Member that is the Leader of this Working Group).

Number	Title	Leader	Approx. no. participants	Options
1	WG1 - Astatine-211 targetry, production, extraction, back-up, logistics	Dr Sture Lindegren	12	0
2	WG2 - Radiopharmaceuticals: development and preclinical Proof Of Concept	Dr Joelle Gaschet	30	0
3	WG3 - Improving Dosimetry for Optimizing Targeted Alpha Therapy with astatine-211	Dr Stig Palm	17	0
4	WG4 - Clinical applications in Nuclear Medicine	Dr JOSE REINALDO CHICHARO DE FREITAS	18	0
5	WG5 - Valorisation of project results: exploitation, dissemination, communication	Dr Dana Niculae	21	0

### **STSM Coordinators history**

STSM Coordinator	Assigned By	Start date	End date	Status	Options
✓ Dr Marek Pruszynski (Current)	Ms Jeannette Nchung Oru	2020-10-23		Assigned	

# **Science Communication Manager**

Name	Start date	Status	Options
✔ Prof Emilija Janevik-Ivanovska	2020-10-23	Assigned	

## ITC CG Coordinators history

✓ Dr Penelope Bouziotis (Current)	Ms Jeannette Nchung Oru	2020-10-23		Assigned	
ITC CG Coordinator	Assigned By	Start date	End date	Status	Options

#### **Grant Periods**

Period			GH FR			Status
1. 2020-11-01 to 2021-04-30	GIP ARRONAX	2	2	2	2	AGA WBP Pending MC Vote

Initial FSAC percentage (MAX 15%)